These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

116 related items for PubMed ID: 9288168

  • 1. Substituted (pyridylmethoxy)naphthalenes as potent and orally active 5-lipoxygenase inhibitors; synthesis, biological profile, and pharmacokinetics of L-739,010.
    Hamel P, Riendeau D, Brideau C, Chan CC, Desmarais S, Delorme D, Dubé D, Ducharme Y, Ethier D, Grimm E, Falgueyret JP, Guay J, Jones TR, Kwong E, McAuliffe M, McFarlane CS, Piechuta H, Roumi M, Tagari P, Young RN, Girard Y.
    J Med Chem; 1997 Aug 29; 40(18):2866-75. PubMed ID: 9288168
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Naphthalenic lignan lactones as selective, nonredox 5-lipoxygenase inhibitors. Synthesis and biological activity of (methoxyalkyl)thiazole and methoxytetrahydropyran hybrids.
    Ducharme Y, Brideau C, Dubé D, Chan CC, Falgueyret JP, Gillard JW, Guay J, Hutchinson JH, McFarlane CS, Riendeau D.
    J Med Chem; 1994 Feb 18; 37(4):512-8. PubMed ID: 8120869
    [Abstract] [Full Text] [Related]

  • 8. Preclinical pharmacokinetics and metabolism of 6-(4-(2,5-difluorophenyl)oxazol-5-yl)-3-isopropyl-[1,2,4]-triazolo[4,3-a]pyridine, a novel and selective p38alpha inhibitor: identification of an active metabolite in preclinical species and human liver microsomes.
    Kalgutkar AS, Hatch HL, Kosea F, Nguyen HT, Choo EF, McClure KF, Taylor TJ, Henne KR, Kuperman AV, Dombroski MA, Letavic MA.
    Biopharm Drug Dispos; 2006 Nov 18; 27(8):371-86. PubMed ID: 16944451
    [Abstract] [Full Text] [Related]

  • 9. Rofecoxib [Vioxx, MK-0966; 4-(4'-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles.
    Chan CC, Boyce S, Brideau C, Charleson S, Cromlish W, Ethier D, Evans J, Ford-Hutchinson AW, Forrest MJ, Gauthier JY, Gordon R, Gresser M, Guay J, Kargman S, Kennedy B, Leblanc Y, Leger S, Mancini J, O'Neill GP, Ouellet M, Patrick D, Percival MD, Perrier H, Prasit P, Rodger I.
    J Pharmacol Exp Ther; 1999 Aug 18; 290(2):551-60. PubMed ID: 10411562
    [Abstract] [Full Text] [Related]

  • 10. Pharmacology of MK-0591 (3-[1-(4-chlorobenzyl)-3-(t-butylthio)-5-(quinolin-2-yl-methoxy)- indol-2-yl]-2,2-dimethyl propanoic acid), a potent, orally active leukotriene biosynthesis inhibitor.
    Brideau C, Chan C, Charleson S, Denis D, Evans JF, Ford-Hutchinson AW, Fortin R, Gillard JW, Guay J, Guévremont D.
    Can J Physiol Pharmacol; 1992 Jun 18; 70(6):799-807. PubMed ID: 1330258
    [Abstract] [Full Text] [Related]

  • 11. Pharmacodynamic and pharmacokinetic characterisation of RBx 7796: a novel 5-lipoxygenase inhibitor.
    Shirumalla RK, Sharma P, Dastidar SG, Paliwal JK, Kakar S, Varshney B, Singh Saini G, Sattigeri V, Salman M, Ray A.
    Inflamm Res; 2008 Mar 18; 57(3):135-43. PubMed ID: 18369577
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Nonsteroidal anti-inflammatory drugs as scaffolds for the design of 5-lipoxygenase inhibitors.
    Kolasa T, Brooks CD, Rodriques KE, Summers JB, Dellaria JF, Hulkower KI, Bouska J, Bell RL, Carter GW.
    J Med Chem; 1997 Feb 28; 40(5):819-24. PubMed ID: 9057869
    [Abstract] [Full Text] [Related]

  • 16. BAY X1005, a new inhibitor of leukotriene synthesis: in vivo inflammation pharmacology and pharmacokinetics.
    Müller-Peddinghaus R, Kohlsdorfer C, Theisen-Popp P, Fruchtmann R, Perzborn E, Beckermann B, Bühner K, Ahr HJ, Mohrs KH.
    J Pharmacol Exp Ther; 1993 Oct 28; 267(1):51-7. PubMed ID: 8229782
    [Abstract] [Full Text] [Related]

  • 17. Development of 2,3-dihydro-6-(3-phenoxypropyl)-2-(2-phenylethyl)-5-benzofuranol (L-670,630) as a potent and orally active inhibitor of 5-lipoxygenase.
    Lau CK, Bélanger PC, Dufresne C, Scheigetz J, Therien M, Fitzsimmons B, Young RN, Ford-Hutchinson AW, Riendeau D, Denis D.
    J Med Chem; 1992 Apr 03; 35(7):1299-318. PubMed ID: 1313879
    [Abstract] [Full Text] [Related]

  • 18. A novel class of orally active non-peptide bradykinin B2 receptor antagonists. 1. Construction of the basic framework.
    Abe Y, Kayakiri H, Satoh S, Inoue T, Sawada Y, Imai K, Inamura N, Asano M, Hatori C, Katayama A, Oku T, Tanaka H.
    J Med Chem; 1998 Feb 12; 41(4):564-78. PubMed ID: 9484506
    [Abstract] [Full Text] [Related]

  • 19. Quinolines as potent 5-lipoxygenase inhibitors: synthesis and biological profile of L-746,530.
    Dubé D, Blouin M, Brideau C, Chan CC, Desmarais S, Ethier D, Falgueyret JP, Friesen RW, Girard M, Girard Y, Guay J, Riendeau D, Tagari P, Young RN.
    Bioorg Med Chem Lett; 1998 May 19; 8(10):1255-60. PubMed ID: 9871745
    [Abstract] [Full Text] [Related]

  • 20. L-663,536 (MK-886) (3-[1-(4-chlorobenzyl)-3-t-butyl-thio-5-isopropylindol-2-yl]-2,2 - dimethylpropanoic acid), a novel, orally active leukotriene biosynthesis inhibitor.
    Gillard J, Ford-Hutchinson AW, Chan C, Charleson S, Denis D, Foster A, Fortin R, Leger S, McFarlane CS, Morton H.
    Can J Physiol Pharmacol; 1989 May 19; 67(5):456-64. PubMed ID: 2548691
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.